IGF1 and ovarian carcinoma: At the same time, an increase in VASH1 enhances tumor sensitivity to chemotherapy.24 In colon cancer, overexpression of VASH1 remarkably reduces growth, movement, and clonogenic capacity.25 In ovarian cancer, VASH1 inhibits the expression of IGF-1 and inhibits angiogenesis.17 This further suggests that VASH1 may act as an antitumor agent through diverse mechanisms.